Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | CNR2 | P34972 | 3/20 | 0.78 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13518460 | 1.00 | CNR1 (0.82) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL15526206 | 0.95 | CNR1 (0.79) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL15526205 | 0.95 | CNR1 (0.79) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL10600938 | 0.92 | CNR1 (0.85) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL1228084 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL2193040 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL9212287 | 0.89 | CNR1 (0.76) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL11873793 | 0.89 | CNR1 (0.76) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL10600663 | 0.89 | CNR1 (0.76) | CNR1ALDH1A1CNR2FAAHTRPV1 | |
| SCHEMBL15526146 | 0.89 | CNR1 (0.73) | CNR1ALDH1A1CNR2FAAHTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847178-B1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | US HEALTH (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2847178-B1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | US HEALTH (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9422308-B2 | Derivatives of docosahexaenoylethanolamide and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422308-B2 | Derivatives of docosahexaenoylethanolamide and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422308-B2 | Derivatives of docosahexaenoylethanolamide and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-23 | — | — | US | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2847178-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
| EP-2701509-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2013158302-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013158302-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2012149352-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | GAP43, DGAT2, DCX | CNR1 502/4885ALDH1A1 1313/4885CNR2 328/4885 |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | SCD, SCD5, FASN | CNR1 2153/4885ALDH1A1 385/4885CNR2 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.